Iron out KRAS-driven cancer.

Guang Lei, Boyi Gan

The Journal of experimental medicine 2022 Apr 04

filter terms:

all
compound
show more »
show less «

How to specifically target oncogenic KRAS-driven cancers while sparing normal tissues remains an unmet need in cancer therapy. In this issue of JEM, Jiang et al. (2022. J. Exp. Med.https://doi.org/10.1084/jem.20210739) leveraged KRAS-induced iron addiction in cancer cells to design a clever drug delivery approach to enable selective inhibition of KRAS signaling in mutant KRAS tumors but not in normal tissues, offering a new strategy for treating this largely incurable disease. © 2022 Lei and Gan.